Aigen Investment Management LP Boosts Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Aigen Investment Management LP raised its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 23.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,103 shares of the company’s stock after acquiring an additional 3,683 shares during the quarter. Aigen Investment Management LP’s holdings in Guardant Health were worth $438,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Swiss National Bank raised its stake in Guardant Health by 3.3% during the 1st quarter. Swiss National Bank now owns 227,700 shares of the company’s stock worth $4,697,000 after acquiring an additional 7,300 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in Guardant Health by 254.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 114,125 shares of the company’s stock worth $2,354,000 after buying an additional 81,887 shares during the last quarter. First Light Asset Management LLC increased its position in Guardant Health by 119.7% during the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock worth $12,042,000 after buying an additional 227,202 shares during the period. International Assets Investment Management LLC lifted its stake in Guardant Health by 2,193.9% in the third quarter. International Assets Investment Management LLC now owns 10,208 shares of the company’s stock valued at $2,340,000 after buying an additional 9,763 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Guardant Health in the second quarter valued at approximately $831,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

NASDAQ:GH opened at $30.21 on Friday. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. The company has a market capitalization of $3.73 billion, a P/E ratio of -7.13 and a beta of 1.11. The firm has a 50-day moving average price of $23.57 and a two-hundred day moving average price of $26.33. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $37.04.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The company had revenue of $191.48 million during the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.73) EPS. As a group, research analysts expect that Guardant Health, Inc. will post -3.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on GH shares. Sanford C. Bernstein reduced their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group increased their target price on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Leerink Partners dropped their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. UBS Group increased their price objective on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Finally, Piper Sandler boosted their target price on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.60.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.